Using three different Fcγ receptor (FcγR)-deficient mouse strains, we examined the induction of autoimmune hemolytic anemia by each of the four immunoglobulin (Ig)G isotype-switch variants of a 4C8 IgM antierythrocyte autoantibody and its relation to the contributions of the two FcγR, FcγRI, and FcγRIII, operative in the phagocytosis of opsonized particles. We found that the four IgG isotypes of this antibody displayed striking differences in pathogenicity, which were related to their respective capacity to interact in vivo with the two phagocytic FcγRs, defined as follows: IgG2a > IgG2b > IgG3/IgG1 for FcγRI, and IgG2a > IgG1 > IgG2b > IgG3 for FcγRIII. Accordingly, the IgG2a autoantibody exhibited the highest pathogenicity, ∼20–100-fold more potent than its IgG1 and IgG2b variants, respectively, while the IgG3 variant, which displays little interaction with these FcγRs, was not pathogenic at all. An unexpected critical role of the low-affinity FcγRIII was revealed by the use of two different IgG2a anti–red blood cell autoantibodies, which displayed a striking preferential utilization of FcγRIII, compared with the high-affinity FcγRI. This demonstration of the respective roles in vivo of four different IgG isotypes, and of two phagocytic FcγRs, in autoimmune hemolytic anemia highlights the major importance of the regulation of IgG isotype responses in autoantibody-mediated pathology and humoral immunity.
Skip Nav Destination
Article navigation
17 April 2000
Article|
April 10 2000
Markedly Different Pathogenicity of Four Immunoglobulin G Isotype-Switch Variants of an Antierythrocyte Autoantibody Is Based on Their Capacity to Interact in Vivo with the Low-Affinity Fcγ Receptor III
Liliane Fossati-Jimack,
Liliane Fossati-Jimack
aDepartment of Pathology, University of Geneva, 1211 Geneva 4, Switzerland
Search for other works by this author on:
Andreea Ioan-Facsinay,
Andreea Ioan-Facsinay
bDepartment of Human and Clinical Genetics, Leiden University Medical Center, 2300 RA Leiden, The Netherlands
Search for other works by this author on:
Luc Reininger,
Luc Reininger
cInstitut National de la Santé et de la Recherche Médicale U 399, F-13385 Marseille, France
Search for other works by this author on:
Yves Chicheportiche,
Yves Chicheportiche
aDepartment of Pathology, University of Geneva, 1211 Geneva 4, Switzerland
Search for other works by this author on:
Norihiko Watanabe,
Norihiko Watanabe
dDepartment of Molecular Genetics, Chiba University Graduate School of Medicine, Chiba 260, Japan
Search for other works by this author on:
Takashi Saito,
Takashi Saito
dDepartment of Molecular Genetics, Chiba University Graduate School of Medicine, Chiba 260, Japan
Search for other works by this author on:
Frans M. A. Hofhuis,
Frans M. A. Hofhuis
eDepartment of Immunology, University Hospital Utrecht, 3508 GA Utrecht, The Netherlands
Search for other works by this author on:
J. Engelbert Gessner,
J. Engelbert Gessner
fDepartment of Clinical Immunology, Hannover Medical School, 30625 Hannover, Germany
Search for other works by this author on:
Carsten Schiller,
Carsten Schiller
fDepartment of Clinical Immunology, Hannover Medical School, 30625 Hannover, Germany
Search for other works by this author on:
Reinhold E. Schmidt,
Reinhold E. Schmidt
fDepartment of Clinical Immunology, Hannover Medical School, 30625 Hannover, Germany
Search for other works by this author on:
Tasuku Honjo,
Tasuku Honjo
gDepartment of Medical Chemistry, Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan
Search for other works by this author on:
J. Sjef Verbeek,
J. Sjef Verbeek
bDepartment of Human and Clinical Genetics, Leiden University Medical Center, 2300 RA Leiden, The Netherlands
Search for other works by this author on:
Shozo Izui
Shozo Izui
aDepartment of Pathology, University of Geneva, 1211 Geneva 4, Switzerland
Search for other works by this author on:
Liliane Fossati-Jimack
aDepartment of Pathology, University of Geneva, 1211 Geneva 4, Switzerland
Andreea Ioan-Facsinay
bDepartment of Human and Clinical Genetics, Leiden University Medical Center, 2300 RA Leiden, The Netherlands
Luc Reininger
cInstitut National de la Santé et de la Recherche Médicale U 399, F-13385 Marseille, France
Yves Chicheportiche
aDepartment of Pathology, University of Geneva, 1211 Geneva 4, Switzerland
Norihiko Watanabe
dDepartment of Molecular Genetics, Chiba University Graduate School of Medicine, Chiba 260, Japan
Takashi Saito
dDepartment of Molecular Genetics, Chiba University Graduate School of Medicine, Chiba 260, Japan
Frans M. A. Hofhuis
eDepartment of Immunology, University Hospital Utrecht, 3508 GA Utrecht, The Netherlands
J. Engelbert Gessner
fDepartment of Clinical Immunology, Hannover Medical School, 30625 Hannover, Germany
Carsten Schiller
fDepartment of Clinical Immunology, Hannover Medical School, 30625 Hannover, Germany
Reinhold E. Schmidt
fDepartment of Clinical Immunology, Hannover Medical School, 30625 Hannover, Germany
Tasuku Honjo
gDepartment of Medical Chemistry, Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan
J. Sjef Verbeek
bDepartment of Human and Clinical Genetics, Leiden University Medical Center, 2300 RA Leiden, The Netherlands
Shozo Izui
aDepartment of Pathology, University of Geneva, 1211 Geneva 4, Switzerland
Abbreviations used in this paper: FcγR, Fc receptor; FcRγ, FcR common γ chain; Ht, hematocrit; IC, immune complex; WT, wild-type.
Received:
November 30 1999
Revision Requested:
January 20 2000
Accepted:
January 28 2000
Online ISSN: 1540-9538
Print ISSN: 0022-1007
© 2000 The Rockefeller University Press
2000
The Rockefeller University Press
J Exp Med (2000) 191 (8): 1293–1302.
Article history
Received:
November 30 1999
Revision Requested:
January 20 2000
Accepted:
January 28 2000
Citation
Liliane Fossati-Jimack, Andreea Ioan-Facsinay, Luc Reininger, Yves Chicheportiche, Norihiko Watanabe, Takashi Saito, Frans M. A. Hofhuis, J. Engelbert Gessner, Carsten Schiller, Reinhold E. Schmidt, Tasuku Honjo, J. Sjef Verbeek, Shozo Izui; Markedly Different Pathogenicity of Four Immunoglobulin G Isotype-Switch Variants of an Antierythrocyte Autoantibody Is Based on Their Capacity to Interact in Vivo with the Low-Affinity Fcγ Receptor III. J Exp Med 17 April 2000; 191 (8): 1293–1302. doi: https://doi.org/10.1084/jem.191.8.1293
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement